Compare CAPT & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPT | NOTV |
|---|---|---|
| Founded | 2005 | 1974 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | CAPT | NOTV |
|---|---|---|
| Price | $0.63 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 01-01-0001 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $17,389,944.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 84.70 | 4.54 |
| 52 Week Low | $0.37 | $0.66 |
| 52 Week High | $1.94 | $6.48 |
| Indicator | CAPT | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 36.67 |
| Support Level | $0.71 | $0.84 |
| Resistance Level | $0.88 | $0.95 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 6.95 | 39.36 |
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.